AnHeart Therapeutics Won the 2019 Sullivan China New Economy – Excellence in Innovation Award
Frost & Sullivan, the world leading growth consulting company, awarded AnHeart Therapeutics (Hangzhou) Co., Ltd. (“AnHeart”). The 2019 Sullivan China New Economy–Excellence in Innovation Award. AnHeart was selected based on an analysis of the global innovative drug market and evaluation of the relevant companies in the industry. Sun Wei, partner in Commerce & Finance Law Offices, and Mao Huawei, the Executive Director of Frost & Sullivan, presented the award to Dr. Wang Junyuan, CEO of AnHeart.